Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Interim Results

16 Aug 2016 12:00

RNS Number : 3162H
Ovoca Gold PLC
16 August 2016
 

Ovoca Gold PLC

16 August 2016

 

Ovoca Gold plc ("Ovoca" or the "Company")

2016 Interim Results

 

Ovoca Gold is pleased to announce its interim financial statements and report covering the six-month period from 1 January 2016 to 30 June 2016.

 

Please click on the following link to view the full Half Year Report:

 

http://www.rns-pdf.londonstockexchange.com/rns/3162H_-2016-8-16.pdf

 

Highlights:

 

· Cash and cash equivalents and available for sale financial assets of Euro 26.7 million as at 30 June 2016;

· Total comprehensive profit for the six-month period to 30 June 2016 of Euro 6.4 million;

· Dividend income received during the period of US$122,000 from our holding of Polymetal International Plc shares; and

· Cash payment of Euro 0.7 million received during the period relating to the Taymura LLC debt, which we continue to pursue through bankruptcy proceedings.

 

 

 

CEO's Statement

 

Dear shareholders,

 

It is my pleasure to report to you our financials and the results of our work for the first half of 2016.

 

The global market recovery of the gold mining sector positively reflected on our investment portfolio and boosted our financial position. This sector recovery has also brought renewed attention to our Stakhanovsky project. Management is using this time to continue the search for an investor for the Stakhanovsky project.

 

In addition to our gold activities, we also remained very active with litigation regarding our outstanding loan to Taymura LLC, which was declared bankrupt in February 2016. During the six-month period to 30 June 2016, Ovoca recovered US$740,621 in respect of assigned receivables in relation to this loan. Despite the unconstructive legal tactics Taymura LLC beneficiaries have been using, management still believes there is a strong chance to achieve substantial repayment of the Company's loan. We will continue to vigorously defend our interests in the bankruptcy procedure of Taymura LLC and seek all legal options available to us for the benefit of the Company.

 

Ovoca has a strong balance sheet and is entering a market upturn in commodities. As such, management is positive for 2016 and looks forward the next half of the year.

 

 

Sincerely,

 

Kirill Golovanov

CEO

 

ENDS

 

Enquiries:

 

Ovoca Gold plc

Kirill Golovanov, Chief Executive Officer

 

Tel: + 7 495 916 6029

Davy - NOMAD, ESM Adviser and Broker

Tel: +353 (1) 679 6363

John Frain / Daragh O'Reilly

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EAEPKFLFKEFF
Date   Source Headline
5th Feb 20267:00 amRNSChange of Name
28th Jan 20268:00 amRNSReadmission - Ovoca Bio PLC
28th Jan 20267:00 amRNSFirst Day of Dealings on AIM
27th Jan 20262:32 pmRNSResult of Meeting
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20257:00 amRNSNotice of AGM
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSNotice of AGM
13th Nov 20257:00 amRNSChange of Broker
30th Sep 20251:09 pmRNSReplacement Half Year Report
30th Sep 20257:00 amRNSHalf-year Report
26th Jun 20257:00 amRNSPublication of 2024 Annual Report
5th Jun 20257:00 amRNSDelisting from Euronext Growth Exchange
7th May 20257:30 amRNSSuspension - Ovoca Bio plc
7th May 20257:00 amRNSProposed Acquisition, Disposal & Reverse Takeover
3rd Mar 20252:00 pmRNSManagement Changes
18th Dec 20246:00 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM
11th Oct 20245:30 pmRNSHolding(s) in Company
9th Oct 20245:45 pmRNSSale of Treasury Shares
25th Sep 20247:00 amRNSHalf-year Report
2nd Sep 20242:30 pmRNSConsultancy Agreement
15th Jul 20247:00 amRNSDirector/PDMR Shareholding
15th Jul 20247:00 amRNSDirectorate Change
28th Jun 20247:00 amRNSAnnual Financial Report
23rd Jan 20247:00 amRNSHolding(s) in Company
1st Dec 202312:00 pmRNSResult of AGM
7th Nov 20239:15 amRNSNotice of AGM
28th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSSummary Results of Phase II Study for Orenetide
30th Jun 20237:00 amRNSAnnual Financial Report
12th Jun 20237:00 amRNSUpdate on Completion Timelines for Phase II Study
16th Mar 20234:35 pmRNSPrice Monitoring Extension
16th Mar 20232:05 pmRNSSecond Price Monitoring Extn
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 20239:05 amRNSSecond Price Monitoring Extn
16th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20237:00 amRNSDisposal of Russian Assets
14th Feb 20234:41 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20232:05 pmRNSSecond Price Monitoring Extn
14th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSResult of AGM
6th Oct 20222:30 pmRNSNotice of AGM
30th Sep 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.